NCT03304470已完成2 期
A Double-Blind, Randomized, Intraindividual, Vehicle-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Topically Applied ATx201 in Subjects With Moderate Atopic Dermatitis
UNION therapeutics1 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2017年9月25日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- Incidence of local and systemic treatment-emergent adverse events
研究概览
简要总结
This is a Phase 2, 3-week, single-center, double-blind, randomized, two-arm, vehicle controlled study, with each individual receiving both active and vehicle treatment. Approximately 30 subjects with moderate atopic dermatitis will receive topically applied ATx201 CREAM 2% and matching vehicle once daily for 3 weeks (5 mg/cm2/day), without occlusion. ATx201 and vehicle will be applied on two separate target lesions of moderate atopic dermatitis (lesions of at least 3 × 3 cm, excluding the face, scalp, genitals, hands, and feet, ideally from the same anatomical location).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •clinically confirmed diagnosis of active atopic dermatitis
- •at least a 6-month history of atopic dermatitis and had no significant flares in atopic dermatitis for at least 4 weeks before screening
- •≥2 areas of atopic dermatitis (excluding face, scalp, genitals, hands, and feet) of at least 3 × 3 cm; with a lesional TSS of ≥5 at Day 1 for each treatment area
排除标准
- •breastfeeding, pregnant, or is planning to become pregnant during the study.
- •clinically infected atopic dermatitis
- •Fitzpatrick's Skin Phototype ≥5
- •Presence of any tattoos, scratches, open sores, excessive hair, or skin damages in the target lesion areas
- •known to have immune deficiency or is immunocompromised.
- •history of cancer or lymphoproliferative disease within 5 years prior to Day
- •major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study.
- •clinically significant medical condition or physical/laboratory/vital signs abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.
- •known history of chronic infectious disease (e.g., hepatitis B, hepatitis C, or infection with human immunodeficiency virus).
- •used hydroxyzine or diphenhydramine within 1 week prior to Day
- •used dupilumab within 12 weeks prior to Day
- •received any nonbiological investigational product or device within 4 weeks prior to Day 1
- •used crisaborole and any other topical PDE-4 inhibitor within 4 weeks prior to Day
- •used doxepin within 1 week prior to Day
- •used topical products containing urea within 1 week prior to Day
- •used nonurea-containing emollient anywhere on the body from 1 day before Day
- •used systemic antibiotics or topical antibiotics on the treated areas within 2 weeks prior to Day
- •used any topical medicated treatment for atopic dermatitis within 2 weeks prior to Day 1, including, but not limited to, topical corticosteroids, calcineurin inhibitors, tars, bleach, antimicrobials, medical devices, and bleach baths.
- •used systemic treatments (other than biologics) that could affect atopic dermatitis less than 4 weeks prior to Day 1 (e.g., retinoids, calcineurin inhibitors, methotrexate, cyclosporine, hydroxycarbamide [hydroxyurea], azathioprine, oral/injectable corticosteroids).
- •received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day
- •excessive sun exposure, is planning a trip to a sunny climate, has received ultraviolet phototherapy, or has used tanning booths within 4 weeks prior to Day 1, or is not willing to minimize natural and artificial sunlight exposure during the study. Use of sunscreen products (excluding the treatment areas) and protective apparel are recommended when exposure cannot be avoided.
- •known or suspected allergy to ATx201 or any component of the investigational product.
- •known history of clinically significant drug or alcohol abuse in the last year prior to Day
- •history of an allergic reaction or significant sensitivity to lidocaine or other local anesthetics.
- •history of hypertrophic scarring or keloid formation in scars or suture sites.
- •taking anticoagulant medication, such as heparin, low molecular weight-heparin, warfarin, or antiplatelets (nonsteroidal anti-inflammatory drugs and aspirin ≤81 mg will not be considered antiplatelets) within 2 weeks prior to Day 1, or has a contraindication to skin biopsies.
研究组 & 干预措施
ATx201 2% CREAM
Experimental
干预措施: ATx201 2% Cream (Drug)
ATx201 Cream Vehicle
Placebo Comparator
干预措施: ATx201 Cream Vehicle (Drug)
结局指标
主要结局
Incidence of local and systemic treatment-emergent adverse events
时间窗: 34 days
# of TEAEs
次要结局
- Change from baseline in lesional Total Sign Score at Days 8, 15, and 22.(22 Days)
- Change from baseline in lesional Treatment Areas Assessment at Days 8, 15, and 22(22 Days)
- Change from baseline in skin barrier and biomarker levels at Day 22(Day 22)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic DermatitisAtopic DermatitisNCT03954158Pfizer81
已完成
2 期
Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of AcneAcne VulgarisPropionibacterium AcnesAcneNCT00211497BioWest Therapeutics Inc255
已完成
2 期
A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate RosaceaRosaceaNCT03590366AOBiome LLC140
已完成
2 期
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic DermatitisAtopic DermatitisNCT04598269Aclaris Therapeutics, Inc.50
已完成
2 期
B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic DermatitisAtopic DermatitisPruritusNCT04490109AOBiome LLC547